Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer (DVT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00633061
Recruitment Status : Completed
First Posted : March 11, 2008
Last Update Posted : February 7, 2013
Information provided by (Responsible Party):
Janna Journeycake, University of Texas Southwestern Medical Center

Brief Summary:
The primary hypothesis of this study is that occult catheter-related DVT in children with cancer is common and directly contributes to development of serious catheter complications, specifically bacteremia/fungemia and/or recurrent occlusion of the catheter tip. Accordingly, anticoagulant treatment of clinically silent (occult) DVT will reduce rates of catheter-related infection and occlusion, delays in therapy and need for catheter replacement.

Condition or disease Intervention/treatment Phase
Childhood Cancer Central Venous Catheters Deep Vein Thrombosis Catheter-related Infection Catheter-related Occlusion Drug: Enoxaparin Phase 2

Detailed Description:

This is a two-part study with an initial diagnosis component followed by a treatment component. The number of subjects to be consented for the diagnosis component is 350, and 50 for the treatment portion (25 on the observation arm, and 25 for enoxaparin treatment).

Study Procedures:

Patients diagnosed with cancer at the Center for Cancer and Blood Disorders will have a catheter inserted for cancer related treatment. After insertion, eligible patients who provide consent will be enrolled in the diagnosis component of the study. The principal investigator and research team will monitor for catheter complications (occlusion and bacteremia/fungemia). After two complications, participants will be screened for occult CVC-related DVT by contrast venography, ultrasonography, or magnetic resonance venography. If DVT is not diagnosed, participant will go off the study. If DVT is diagnosed, participant will be asked to consent to enroll in the treatment study. After enrollment, participant is randomized between the two arms of observation and enoxaparin treatment. After 6 weeks, patients will have another image; this represents the end of treatment period. After the follow-up imaging, patients will be monitored for 10 weeks to obtain primary outcomes. Once a primary outcome (progression to symptomatic DVT/ PE, blood stream infection or catheter removal) is achieved the participants can be treated with anticoagulation again if necessary, but primary oncologist will determine treatment.


The hypothesis is that the enoxaparin treatment group will have a median adverse catheter event free survival time of 12 weeks versus 4 weeks for the control group with a hazard ration of 0.4. A total sample size of 50 (25 in each arm) will detect such a difference with 90% power at an α=0.05. If there is a drop out rate of 10% in each arm, a difference can still be detected with 80% power.

Approximately 200 to 250 patients are diagnosed with cancer each year at Children's Medical Center Dallas, and based on prior institutional experience, two-thirds will have catheters inserted to facilitate chemotherapy. However, one-quarter of these patients have brain tumors and are not eligible due to the potential increased risk of intracranial hemorrhage with anticoagulation. There will be 100 patients each year who are at risk for CVC-related DVT. Based on previous studies, up to 50% of patients should develop occult DVT; however, only 35% of patients will likely be screened with radiographic imaging. Approximately 17 patients a year enrolled in the diagnosis study may be diagnosed with DVT and eligible for randomization. Therefore, total enrollment will be completed in approximately 3 years with an additional 4 months necessary to complete the follow-up period.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study on the Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
Study Start Date : March 2008
Actual Primary Completion Date : June 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: A
Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
Drug: Enoxaparin
Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children >2 months and 1.5 mg/kg every 12 hours for infants <2 months. Duration of treatment is 6 weeks.
Other Name: Lovenox
No Intervention: B
Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks

Primary Outcome Measures :
  1. Composite endpoint: catheter removal, signs and symptoms of DVT or PE, OR bacteremia/fungemia [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Bleeding complications associated with enoxaparin therapy, need for additional platelets [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of cancer
  2. Age ≤ 18 years
  3. First tunneled central venous catheter (implanted port or external) inserted in the upper venous system (subclavian, brachiocephalic, or jugular vein) within the previous 2 weeks
  4. Catheter expected to be in place for duration of chemotherapy (≥ 3 months)
  5. History of no more than one catheter complication (occlusion or infection)

Exclusion Criteria:

  1. Prior history of DVT
  2. Currently receiving an anticoagulant or anti-platelet agents on a daily basis
  3. Diagnosis of high grade malignant brain tumor or metastasis to the brain
  4. Clinical signs/symptoms of DVT
  5. Clinical signs/symptoms of Pulmonary embolism
  6. Renal failure
  7. Recent major hemorrhage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00633061

United States, Texas
Children's Medical Center
Dallas, Texas, United States, 75235
Sponsors and Collaborators
University of Texas Southwestern Medical Center
Principal Investigator: Janna Journeycake, MD University of Texas

Responsible Party: Janna Journeycake, Associate Professor of Pediatrics, University of Texas Southwestern Medical Center Identifier: NCT00633061     History of Changes
Other Study ID Numbers: K23HL084097 ( U.S. NIH Grant/Contract )
IRB # 122007-062
First Posted: March 11, 2008    Key Record Dates
Last Update Posted: February 7, 2013
Last Verified: February 2013

Keywords provided by Janna Journeycake, University of Texas Southwestern Medical Center:
Childhood Cancer
Central Venous Catheter
Deep Vein Thrombosis
Catheter-related Infection
Catheter-related Occlusion

Additional relevant MeSH terms:
Venous Thrombosis
Catheter-Related Infections
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action